Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01583283 · ClinicalTrials.gov registry record · Phase 1
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01583283 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 38 participants.
The verdict
NCT01583283, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Once determined, the purpose of this study will be to determine the efficacy of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma who have had 1-3 prior therapies and who are not lenalidomide-refractory.
Interventions
- DRUG Dexamethasone
- DRUG lenalidomide
- DRUG ACY-1215
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-07-12 |
| Est. Completion | 2021-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01583283
The ClinicalTrials.gov registry entry for NCT01583283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01583283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01583283 about?
NCT01583283 is a clinical study titled "Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma". The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Once determined, the purpose of this study will be to determine the efficacy of ACY-1215 in combination with lenal...
What is the current status of trial NCT01583283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2012-07-12. Estimated completion is 2021-03-24.
What interventions are being tested in trial NCT01583283?
The interventions under investigation include: Dexamethasone (DRUG), lenalidomide (DRUG), ACY-1215 (DRUG).
Who is sponsoring clinical trial NCT01583283?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.